159 results about "Bone Marrow Stem Cell" patented technology

The present invention relates to a method for isolating and culturing adult stem cells derived from human amniotic membrane in high yield, and more particularly to a method for obtaining a large amount of adult stem cells, the method comprising obtaining amniotic epithelial cells from human amniotic tissue in high yield by treatment with dithiothreitol (DTT) and a low concentration of trypsin and culturing the amniotic epithelial cells in a medium containing a Rho-associated kinase inhibitor. The human amniotic epithelial cell-derived stem cells are easily extracted compared to existing therapeutic stem cells such as umbilical cord blood stem cells and bone marrow stem cells, the yield and proliferation thereof are significantly increased by DTT treatment, the addition of the ROCK inhibitor or the replacement of medium. Thus, the method can be used to efficiently prepare adult stem cells.

Disclosed are methods and compositions for delivering a therapeutic agent to target organs or tissues, such as brain. The methods and compositions use bone marrow stem cells, monocytes, macrophages or microglial cells to deliver the therapeutic agent associated with nanoparticles to the target organ or tissue.

Methods for obtaining osteoprogenitors, osteoblasts or osteoblast phenotype cells, as well as cell populations including such cells, from human bone marrow stem cells in vitro or ex vivo are disclosed. Bone marrow stem cells are contacted with human serum or plasma and a growth factor or a biologically active variant or derivative thereof. In addition, osteoprogenitor, osteoblast or osteoblast phenotype cell types and cell populations are provided. The cell populations may include additional cell types, such as endothelial cells or progenitors. The osteoprogenitors, osteoblasts or osteoblast phenotype cells may be used in therapy, particularly bone therapy.

Intravenous administration of bone marrow cells collected from rat bone marrow to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

The present invention provides a bone marrow stem cell protection solution, which is mainly prepared by dissolving a hypoxic protection agent, heparin sodium and an aminoglycoside antibiotic in a DMEM/F12 culture medium aqueous solution, wherein per mL of the DMEM/F12 culture medium aqueous solution can respectively dissolve 5-10 mg of the hypoxic protection agent, 0.01-0.05 U of the heparin sodium and 50-200 U of the aminoglycoside antibiotic, and the concentration of the DMEM/F12 culture medium aqueous solution is 30-40 mg/ml. According to the present invention, the bone marrow stem cell protection solution has advantages of stable performance, safety and no toxicity, can effectively protect bone marrow stem cells, can make bone marrow stem cells be preserved for a long time and can maintain the cell activity in vitro, can maintain the original multidirectional differentiation ability, and can expand the clinical application of bone marrow stem cells, wherein the bone marrow stem cells can be transported to most domestic cities and neighboring countries by using the existing transportation tools.

The invention relates to an individualized biomimetic dental implant and a manufacture method thereof. The invention is characterized in that the dental implant comprises an implant body for imitating the original tooth root tissue structure of a patient's missing tooth and also comprises a biomimetic artificial alveolar bone structure outer-layer for imitating a patient's alveolar bone tissue structure. The biomimetic artificial alveolar bone structure outer-layer and the external surface of the implant body are combined as a whole. The biomimetic tooth root implant body's outer layer is a 3D printed biomimetic artificial alveolar bone structure outer-layer which is combined with the implant body to form a whole structure, and is similar to the tissue structures of missing tooth's original tooth root and alveolar bone. Thus, the invention provides an ideal implementation scheme of a biomimetic artificial tooth root structure. What is the most important is that the invention provides a structure which is beneficial to bone marrow stem cell and osteogenesis-related cell adhesion, proliferation and mineralization and gives play to final osteogenic function and has good bioactivity. Therefore, a microenvironment for promoting osteogenesis is created, osteocyte generation is induced, and early rapid and firm synosteosis is realized.

In a culture method of the present invention, by culturing bone marrow stromal cells or mesenchymal stem cells under a pseudo micro-gravity environment generated by multi-axis rotation, bone marrow stromal cells or mesenchymal stem cells having an average cell size smaller than that before the culture are obtained. The bone marrow stromal cells or mesenchymal stem cells thus cultured are suitable as graft cells for a central nerve diseases therapy.

The invention relates to a medical dental implant with the surface biomimetic function and a manufacturing method thereof. The medical dental implant is characterized in that the medical dental implant comprises an implant body and further comprises an outer layer of a bionic artificial bone structure, the outer layer is integrally combined with the outer surface of the implant body and capable of simulating the alveolar cavity bone tissue structure around the tooth root portion of a missing tooth of a patient. According to the medical dental implant and the manufacturing method thereof, the outer layer of the bionic bone structure, which is formed in a 3D printing mode and of a massive structure, serves as the outer layer of the tooth implant body, and therefore an ideal embodiment used for simulating the artificial bone surface structure is provided. More importantly, a good activity surface layer structure foundation beneficial to bone marrow stem cell and bone-formation related cell adhesion, proliferation and growth and capable of playing the final bone-formation function is provided, the surface of the foundation is loaded with chemical components such as calcium and phosphate and bioactive molecules such as collagens, hence, a bone-formation promotion microenvironment is created, bone cell generation is induced, and fast and firm bone combination can be achieved at the early stage.

The invention relates to a medicine for treating tumor and hemorrhoid and a manufacturing method thereof. The medicine aims at the disadvantages that: the prior treatment method for removing the hemorrhoid and the tumor can only kill or remove partial tumor cells, has large pain and high recurrence rate during the treatment period, has the phenomena of lassitude, hypodynamia, nausea, vomiting and hemogram reduction during the radiotherapy period, causes low immunity, damages self-immunologic function of a human body, inhibits functions of bone marrow stem cells, is easy to produce drug dependence, and is easy for recurrence. The invention prepares tannic acid, atropine, gallic acid, quinin hydrochloride, ferrous sulfate, caffeine, pure sulfuric acid, urethane, carbolic acid, sterile water and the like, into medicines for local parts of pathological changes, does not hurt normal tissues, has no pain, does not need to treat for a long time, and has the advantages of taking effect by injecting at one time, no recurrence, wide raw materials, low cost, wide clinical application, and small side effect.

A method for treating a degenerative or traumatic injury to a nerve tissue or the brain by administering at or near the injury site a composition containing adherent bone marrow stem cells suspended in a pharmaceutically acceptable liquid in an amount effective to elicit axonal regeneration or re-myelination at the site of injury.

The present invention provides an isolated nucleic acid comprising a promoter operably linked to a nucleic acid encoding a peptide or protein and/or an RNA (e.g., antisense or ribozyme), wherein the promoter comprises elements that can include, but are not limited to, a) a myeloid specific promoter element comprising a core sequence GAGGAA; b) a myeloid specific promoter element comprising a core sequence AAGGAGAAG; c) a myeloid specific promoter element comprising a core sequence TTTCCAAA; d) a myeloid specific promoter element comprising a core sequence TGTGGTTGC; e) a myeloid specific promoter element comprising a core sequence TGAGTCA; f) a myeloid associated promoter element comprising a core sequence CCGCCC; and g) any combination of (a), (b), (c), (d), (e) and/or (f), any combination of multiples of (a), (b), (c), (d), (e) and/or (f), in any order and/or in any orientation (forward or reverse).

The invention relates to a method of the induction and differentiation of the neural stem cells and the neural cells from bone marrow stromal cells which are cultured by autologous bone marrow, autologous serum and autologous cerebrospinal fluid. The method pertains to the methods for differentiating the bone marrow stem cells into the neural stem cells. A conventional low-sugar DMEM/F 12 culture medium is adopted, the autologous serum replaces the original fetal bovine serum, the autologous cerebrospinal fluid replaces the original additive and a stimulating factor, a small amount of autologous bone marrow is used for culturing more cells with the number that can meet the clinical needs. The method has the advantages of low cost and easy material selection, avoiding zoonosis and foreign protein exclusive reaction, and so on. The method of inducing the bone marrow stromal cells into the neural stem cells by using cerebrospinal fluid can effectively solve the shortcomings of the traditional methods.

The invention relates to an individual biomimetic dental implant and a making method thereof, and the individual biomimetic dental implant includes an implant body imitating an original teeth root tissue structure of a missing tooth of a patient, a bionic artificial alveolar bone structure outer layer which is bonded with the outer surface of the implant body into one body, and biological protein molecule-bone morphogenetic protein (BMP) which is attached to the bionic artificial alveolar bone structure outer layer. The implant body and the bionic artificial alveolar bone structure outer layer are overall 3D-printed, and are similar to the original teeth root tissue structure and the alveolar bone tissue structure of the missing tooth of the patient, and the BMP-modified biological protein molecule promoting rapid bone formation is added, so that an ideal bionic artificial teeth root tissue structure is provided. The most important is to provide a good biological activity structure which is conducive to bone marrow stem cell and bone formation-related cell adhesion, proliferation and mineralization to finally play the osteogenic function, a bone formation promotion microenvironment is created, bone cell formation is induced, and early rapid and strong bone combination can be realized.

The present invention provides a method for inducing neural differentiation comprising treating a bone marrow stem cell with a neurotrophic factor and/or dibutyryl cAMP (dbcAMP), wherein the neurotrophic factor comprises glial cell line-derived neurotrophic factor (GDNF) or pituitary adenylate cyclase-activating polypeptide (PACAP).

The invention relates to a rhodiola rosea and a rhodioside application for inducing stem cells to directionally differentiate into hepatocytes, in particular to a compound inducer of the rhodioside and cell growth factor FGF-4 used for inducing mesenchymal stem cells to directionally differentiate into hepatocytes. The rhodiola rosea develops the new application of rhodiola, which induces mesenchymal stem cells and other stem cells to directionally differentiate into hepatocytes in vitro, and provides the effect of the rhodiola rosea and the rhodioside on inducing the adult stem cells to directionally differentiate into hepatocytes, which is beneficial to further research of the in vivo stem cells transplantation for treating acute or chronic hepatic injury and middle-advanced liver disease field, and provides the basic for new drug development.

A method of using fucoidan to enhance stem cell mobilization in a subject, including hematopoietic stem cells (HSCs) and bone marrow stem cells (BMSCs) is provided. In the method, a blended composition of fruits, mushrooms, microorganisms, maternal fluids, and extracts thereof are used to promote trafficking of stem cells, resulting in migration of the stem cells to specific sties of maintenance an and repair within tissues and/or organs. The method also involves the use of fucoidan obtained from particular algae species to support release and circulation of HSCs, as demonstrated by significantly increase circulation of HSCs in the peripheral blood. Increased circulation of HSCs and/or BMSCs and migration towards sites of maintenance and the natural regeneration mechanisms in the body. Further provided is a dosing regimen for the administration of fucoidan and a method of enhancing release and circulation of stem cells.

A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of substances selected from blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3, Spirulina, AFA or effective combinations and derivatives of these. For example, a supplement comprising wild blueberry, green tea extract, carnosine, vitamin D3, and a Spirulina and/or an AFA-Omega (EtOH) exhibited a synergistic and unexpected association with substantially increased proliferation of bone marrow stem cells and CD34+. A therapeutic amount of a substance that is associated with a substantial increase in stem cells may be used to prevent and repair damages tissues of the brain, due to stroke, the heart, due to coronary artery disease or a heart attack.

Disclosed is an isolated bone marrow stem cell (BMSC) having undetectable or low levels of selected cell markers including those typical of endothelial, neuronal and smooth muscle cells. Also disclosed are grafts and pharmaceutical products that include such cells. Methods of making the BMSCs are also provided. The invention has a wide spectrum of useful applications including use in the prevention and treatment of cardiovascular disease.

A population of myeloid-derived suppressor cells and the culture procedure to obtain these in vitro starting with bone marrow cells of mice, other animals and human beings, in the presence of specific cytokine combinations used to determine concentrations, is provided.

A histo-engineered bone tissue is composed of osteocortex frame as externally layer and central loose bone inoculated by bone marrow stem cells. It can be moulding-shape according to the actual operation scope predefined by CT film and CT reconstitution data of deficit part.

Described is a unique class of antiviral molecule that can be applied to control and eliminate HIV infection in patients using myeloablation therapies and replenishment with transformed bone marrow stem cells programmed to express the antiviral molecule. These anti-viral molecules target the HIV genome in a highly conserved domain, and when expressed in cells prior to infection will cause the cell to die upon infection with HIV. Cell death insures no proliferation of new virus. Reconstituting the immune system with cells expressing these antivirals prevents re-establishment of HIV infection from reservoirs in the re-established lymphocyte and macrophage populations. Over time, reservoirs will be depleted entirely, effectively eliminating the virus. In effect, this new type of antiviral can be used to cure HIV infections.